FAQ: CAR T-Cell Therapy
Expert Guidance Frequently Asked Questions About CAR T-Cell Therapy in the Community Setting

Released: February 25, 2020

Expiration: December 19, 2022

Michael R. Bishop
Michael R. Bishop, MD
Jae H. Park
Jae H. Park, MD
Joshua Sasine
Joshua Sasine, MD, PhD

Activity

Progress
1
Course Completed

References

  1. Tisagenlecleucel package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2018.
  2. Axicabtagene ciloleucel package insert. Santa Monica, CA: Kite Pharma, Inc; May 2019.
  3. Wang X, Riviére I. Clinical manufacturing of CAR T cells: Foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.
  4. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017;130:1800.
  5. Locke FL, Neelapu SS, Bartlett NL. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285.
  6. Neelapu S, Locke F, Bartlett N, et al. SCHOLAR-1 versus ZUMA-1: A standardized comparison of outcomes in patients (pts) with refractory, aggressive non-Hodgkin lymphoma (rNHL). NHL023. Clin Lymphoma Myeloma Leuk. 2017;17(suppl 2):S362.
  7. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45.
  8. Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112.
  9. Abramson JS, Lunning M, Palomba ML. Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: Current and future state of the art. Am Soc Clin Oncol Educ Book. 2019;39:446.
  10. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726.
  11. Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26:1855.
  12. Li A. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. Blood. 2018;132:556.